Table 2.
Baseline characteristics of CVOTs involving GLP-1 receptor agonists and key findings.
| LEADER (n= 9340) |
ELIXA (n= 6068) |
SUSTAIN-6 (n=3297) |
EXSCEL (n= 14752) |
Harmony Outcomes (n=9463) | REWIND (n=9901) |
PIONEER 6 (n= 3183) |
AMPLITUDE-O (n=4076) |
|
|---|---|---|---|---|---|---|---|---|
| Drug | Liraglutide | Lixisenatide | Semaglutide | Exenatide | Albiglutide | Dulaglutide | Semaglutide | Efpeglenatide |
| Age, y | 64 ± 7 | 60 ± 10 | 65 ± 7 | 62 ± 9 | 64 ± 7 | 66 ± 7 | 66 ± 7 | 65 ± 8 |
| Sex - Male - Female |
64% 36% |
69% 31% |
61% 39% |
62% 38% |
69% 31% |
54% 46% |
68% 32% |
67% 33% |
| Administration route | Subcutaneous | Subcutaneous | Subcutaneous | Subcutaneous | Subcutaneous | Subcutaneous | Oral | Subcutaneous |
| Dosage | 1.8 mg/d | 10 µg/d or 20 µg/d | 0·5 mg/w or 1 mg/w | 2 mg/w | 1,5 mg/w | 1.5 mg/w | 14 mg/d | 4 mg/w or 6 mg/w |
| HbA1c % | 8.7 ± 1.6 | 7.7 ± 1.3 | 8.7 ± 1.5 | 8.1 ± 1.0 | 8,7 ± 1.5 | 7.3 ± 1.1 | 8.2 ± 1.6 | 8.9 ± 1.5 |
| Established CVD | 81% | 100% | 83% | 73% | 100% | 31% | 85% | 90% |
| History of HF | 18% | 22% | 24% | 16% | 20% | 9% | 12% | 18% |
| Follow up, y (median) | 3.8 | 2.1 | 2.1 | 3.2 | 1.6 | 5.4 | 1.3 | 1.81 |
| Key findings | Significantly reduced the risk of MACE | No significant impact on primary end-point | 26% lower risk of MACE | Exenatide had no impact on primary end-point, | Significantly reduced the risk of MACE | Significantly reduced the risk of MACE | No significant reduction in MACE compared to placebo | Significantly lower risk of MACE and renal outcome events with |
| References | (37) | (38) | (39) | (40) | (41) | (42) | (43) | (44) |
CV, cardiovascular; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; HF, heart failure; MACE, major adverse cardiovascular events; mg, milligram; µg, microgram; w, week; y, year.